Adamis Pharmaceuticals (NASDAQ:ADMP) Stock Moves in a Range: What Next?
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) is moving in range after the company announced the re-election of Howard C. Birndorf, Dennis Carlo, Roshwan A. Blunt, Richard C. Williams, and David J.
Marguglio to the Board of Directors based on the Inspector of Election’s approved results of Adamis 2020 annual shareholder meeting. In addition, as per the Inspector of Election’s report, shareholders approved all proposals considered during the meeting, including approval on an advisory basis of the compensation payable to executives and ratification of the appointment of the 2021 registered public accounting company BDO USA LLP.
The company had previously urged shareholders to re-elect the Board of Directors. In a statement, the company had indicated that it is prioritizing stockholder engagement and getting feedback about its governance, overall strategy, and operational priorities. Adamis said that they acknowledge that a large shareholder cross-section offered an open perspective to the company and its representatives. From now on, the board is committed to factoring shareholders’ perspectives in the company’s long-term plans. So in the coming months, ADMP is a stock to watch.
Market Reaction:
On Tuesday, ADMP stock fell 2.88% at $1.01 with more than 2.86 million shares, compared to its average volume of 8.84 million shares. The stock has moved within a range of $0.9501 – 1.0400 after opening the trade at $1. Over the past 52-week, the stock has been trading within a range of $0.3800 – 2.3400.
